CA3029875C - Inhibiteurs multifonctionnels de voies biologiques de mek/pi3k et mtor/mek/pi3k et procedes therapeutiques les utilisant - Google Patents

Inhibiteurs multifonctionnels de voies biologiques de mek/pi3k et mtor/mek/pi3k et procedes therapeutiques les utilisant Download PDF

Info

Publication number
CA3029875C
CA3029875C CA3029875A CA3029875A CA3029875C CA 3029875 C CA3029875 C CA 3029875C CA 3029875 A CA3029875 A CA 3029875A CA 3029875 A CA3029875 A CA 3029875A CA 3029875 C CA3029875 C CA 3029875C
Authority
CA
Canada
Prior art keywords
cancer
independently
tumors
pi3k
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3029875A
Other languages
English (en)
Other versions
CA3029875A1 (fr
Inventor
Brian D. Ross
Marcian VAN DORT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA3029875A1 publication Critical patent/CA3029875A1/fr
Application granted granted Critical
Publication of CA3029875C publication Critical patent/CA3029875C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Il est décrit des inhibiteurs multifonctionnels de mTOR, MEK et PI3K, ainsi que des compositions les contenant. Les inhibiteurs multifonctionnels peuvent avoir, par exemple, la formule structurale suivante : Il est également décrit des méthodes d'utilisation des inhibiteurs multifonctionnels dans le traitement des maladies et de conditions (comme les cancers) dans lesquels l'inhibition d'un ou de plusieurs inhibiteurs (mTOR, MEK et PI3K) fournissent un avantage.
CA3029875A 2016-07-06 2017-07-06 Inhibiteurs multifonctionnels de voies biologiques de mek/pi3k et mtor/mek/pi3k et procedes therapeutiques les utilisant Active CA3029875C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359001P 2016-07-06 2016-07-06
US62/359,001 2016-07-06
US201762454163P 2017-02-03 2017-02-03
US62/454,163 2017-02-03
PCT/US2017/040866 WO2018009638A1 (fr) 2016-07-06 2017-07-06 Inhibiteurs multifonctionnels de voies biologiques de mek/pi3k et mtor/mek/pi3k et procédés thérapeutiques les utilisant

Publications (2)

Publication Number Publication Date
CA3029875A1 CA3029875A1 (fr) 2018-01-11
CA3029875C true CA3029875C (fr) 2023-12-19

Family

ID=59363277

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3029875A Active CA3029875C (fr) 2016-07-06 2017-07-06 Inhibiteurs multifonctionnels de voies biologiques de mek/pi3k et mtor/mek/pi3k et procedes therapeutiques les utilisant

Country Status (8)

Country Link
US (1) US10919877B2 (fr)
EP (2) EP3481822B1 (fr)
JP (2) JP2019519593A (fr)
CN (1) CN109563088B (fr)
AU (2) AU2017291838B2 (fr)
CA (1) CA3029875C (fr)
ES (2) ES2922898T3 (fr)
WO (1) WO2018009638A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311624B2 (en) 2017-08-11 2022-04-26 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
CN112143700B (zh) * 2019-06-26 2024-07-19 上海细胞治疗集团股份有限公司 制备过表达外源基因的免疫效应细胞的方法
CN117396470A (zh) * 2021-04-09 2024-01-12 巴塞尔大学 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物
WO2022214702A1 (fr) * 2021-04-09 2022-10-13 Universität Basel Dérivé de triazine servant d'inhibiteurs covalents réversibles et irréversibles de pi3k
WO2023170107A1 (fr) 2022-03-07 2023-09-14 Centre Hospitalier Universitaire Vaudois (Chuv) Inhibiteur de pi3k/akt/mtor pour améliorer l'absorption cellulaire d'un produit radiopharmaceutique
JP2023180347A (ja) * 2022-06-09 2023-12-21 国立大学法人金沢大学 ハイブリッド型化合物又はその塩
CN116617227B (zh) * 2023-06-09 2026-05-01 苏州大学 三氟噻吨在治疗脑血管疾病中的应用
WO2025072796A1 (fr) * 2023-09-27 2025-04-03 Totus Medicines Inc. Compositions pharmaceutiques et leurs méthodes d'utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA197701A (fr) 1920-03-02 Mcgoldrick Timothy Coussin de bequille
CA85878A (fr) 1903-08-19 1904-03-08 George W. Peyton Jauge de charpentier
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO2002006213A2 (fr) 2000-07-19 2002-01-24 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
AU2007297212B8 (en) 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
EP2172198B1 (fr) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha INDUCTEUR DE PROTÉINE p27
JP2011515462A (ja) 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
JP5599783B2 (ja) * 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
EP2143819A1 (fr) 2008-07-11 2010-01-13 Siemens Aktiengesellschaft Procédé de revêtement et revêtement anticorrosif pour composants de turbines
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110166191A1 (en) 2010-01-07 2011-07-07 Shijun Zhang 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
GB201007227D0 (en) 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
EP2604601B1 (fr) * 2010-08-10 2016-02-24 Astellas Pharma Inc. Composé hétérocyclique
WO2012068106A2 (fr) 2010-11-15 2012-05-24 Exelixis, Inc. Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication
JP5997763B2 (ja) * 2011-05-19 2016-09-28 フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ タンパク質キナーゼ阻害剤としての大環状化合物
JP5820080B2 (ja) 2011-11-17 2015-11-24 山▲東▼▲軒▼竹医▲葯▼科技有限公司 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤
EP2968345B1 (fr) * 2013-03-13 2017-12-13 The Regents of The University of Michigan Inhibiteurs dual de mek/pi3k et utilisation pour le traitement des maladies de cancer
US9499495B2 (en) * 2013-04-12 2016-11-22 Asana Biosciences, Llc Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
CN105130960B (zh) * 2015-07-31 2018-07-06 沈阳药科大学 1,3,5-三嗪类衍生物及其应用

Also Published As

Publication number Publication date
EP3481822A1 (fr) 2019-05-15
EP4086250A3 (fr) 2023-03-22
EP4086250C0 (fr) 2024-12-11
CA3029875A1 (fr) 2018-01-11
EP4086250B1 (fr) 2024-12-11
US20190224207A1 (en) 2019-07-25
JP2022019812A (ja) 2022-01-27
JP2019519593A (ja) 2019-07-11
ES2922898T3 (es) 2022-09-21
AU2017291838B2 (en) 2021-01-28
EP3481822B1 (fr) 2022-06-22
AU2021202619A1 (en) 2021-05-27
EP4086250A2 (fr) 2022-11-09
AU2021202619B2 (en) 2022-03-10
US10919877B2 (en) 2021-02-16
CN109563088A (zh) 2019-04-02
AU2017291838A1 (en) 2019-01-17
JP7475062B2 (ja) 2024-04-26
CN109563088B (zh) 2022-10-11
ES3002745T3 (en) 2025-03-07
WO2018009638A1 (fr) 2018-01-11

Similar Documents

Publication Publication Date Title
AU2021202619B2 (en) Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
EP2968345B1 (fr) Inhibiteurs dual de mek/pi3k et utilisation pour le traitement des maladies de cancer
EP4034132B1 (fr) Agents de dégradation de l'erk5 utilisés comme agents thérapeutiques dans le cancer et les maladies inflammatoires
US20110319362A1 (en) Stat3 ligands and therapeutic uses thereof
JP2013503837A (ja) ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
JP6637890B2 (ja) ベンズアミド及びニコチンアミド化合物及びこれを使用する方法
JP2024525740A (ja) 小分子サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）およびｉｋｚｆ２（ｈｅｌｉｏｓ）分解剤並びにその使用方法
CA2882157A1 (fr) Composes azaindole substitue, leurs sels, leurs compositions pharmaceutiques et leurs procedes d'utilisation
CN106459011B (zh) 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途
EP4460306A2 (fr) Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg)
AU2018316175A1 (en) Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
WO2025207686A2 (fr) Composés contenant du bore modifié à petites molécules et leurs procédés d'utilisation
JP2024538132A (ja) Ｄｏｔ１ｌ分解のための小分子およびその使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220210

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250701

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250701